Prevenar 13

Non-Hodgkin Lymphoma

Poitiers University HospitalvaccinePhase 4 / ApprovedActive

B

59/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 50/ 100
Competitive Position: 73/ 100

Competitive context

372 Active assets in the Non-Hodgkin Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Cyclosporin A Memorial Sloan Kettering Cancer Center	Phase 3	BBB
Pegaspargase Ciusss de L'Est de l'Île de Montréal	Phase 4	BBB
Adriamycin National Cancer Institute (NCI)	Phase 4	BBB
Prednisolone Mwanasha Merrill, MD	Phase 3	BBB
Entecavir Fudan University	Phase 4	BBB

View all 50 →

Same molecule, other indications

Prevenar 13 is also rated in:

pneumococcal infectionActive

BBB

Indicative · Phase 4

72 / 100

sickle cell diseaseDormant

B

Indicative · Phase 2

57 / 100

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant

CCC

Indicative · Phase 3

54 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.